Status:
WITHDRAWN
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Myeloid Malignancy
Myeloid Malignancies
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This research study is evaluating the feasibility of conducting cancer genetic testing using healthy skin cells among participants with a diagnosis of a blood cancer. Additionally, investigators will ...
Detailed Description
The purpose of this prospective, non-randomized, non-therapeutic, single arm study is to determine the feasibility and benefit of performing genetic testing for all participants with a blood cancer di...
Eligibility Criteria
Inclusion
- Age of 18 years or older
- Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
- Ability to understand and provide a signed and completed consent document in English or Spanish.
Exclusion
- Patients with who cannot safely undergo skin biopsy as adjudicated by the study team.
- Patients who have previously undergone germline genetic testing for predisposition to myeloid malignancies
Key Trial Info
Start Date :
July 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2029
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06543511
Start Date
July 29 2024
End Date
July 1 2029
Last Update
November 22 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.